Pep Grading
United StatesSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Semaglutide reduced cardiovascular events in obese patients with cardiovascular disease but without diabetes.
Semaglutide
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first FDA-approved December 5, 2017, it is backed by the extensive STEP and SUSTAIN trial programs involving thousands of patients. There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Metabolic / GLP-1 AgonistGLP-1 Receptor ActivationWeight ManagementMetabolic HealthCardiovascular
- Vendors
- 7 vendors
- Sizes
- 5 mg – 50 mg
- Intake
- Injections · Oral
Typical dose
0.25-2.4mg weekly
Weekly, increase every 4 weeks
Route
Subcutaneous weekly
Inject once weekly on the same day each week. Can be taken with or without food.
Cycle
16–20+ weeks; ongoing for weight management
Typical duration
Storage
2-8°C
Follow vendor guidance
Marketplace
Vendor listings
7 offers for Semaglutide
| Vendor | Price | Rating | Shipping | COA | Action |
|---|---|---|---|---|---|
Crownwell Research
| $30.00 $40.00 $6.00/mg −25% | No reviews | 1-5 days United States | 2 files | |
prpeps
| $40.00 $4.00/mg | No reviews | 2 days United States | None | |
Vertex Labs
| $44.10 $49.00 $4.41/mg −10% | No reviews | 3 days United States | 2 files | |
bioinfinity
| $45.00 $9.00/mg | No reviews | 3–5 days United States, Puerto Rico | 1 file | |
Trulab Peptides
| $59.00 $11.80/mg | No reviews | 2–5 days Worldwide | 1 file | |
American Peptides
| $60.00 $12.00/mg | No reviews | 1-2 days United States | 2 files | |
primepepsolutions
| $69.99 $7.00/mg | No reviews | 1–3 days Worldwide | None |
What the research reports
Reported research benefits.
Outcomes described across the published literature and ongoing study, not promised results. Read each as research context, not a personal guarantee.
01
Weight loss
02
Appetite suppression
03
Glycemic control
04
Metabolic health
Dosage and protocol
How it is typically studied.
Semaglutide is a GLP-1 receptor agonist prescribed for weight management and diabetes. Dosing follows a titration schedule starting low and increasing over weeks to minimize side effects. Half-life: ~7 days. Inject once weekly on the same day each week.
01 Route
Subcutaneous weekly, Oral tablet daily
02 Example range
0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
03 Frequency
Weekly, increase every 4 weeks
04 Timing
Inject once weekly on the same day each week. Can be taken with or without food.
Educational reference only. Use clinician guidance for dosing decisions.
Evidence
What the studies actually show.
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Oral semaglutide reduced major adverse cardiovascular events vs placebo in high-risk type 2 diabetes.
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
SOUL trial design for assessing oral semaglutide effects on cardiovascular outcomes in type 2 diabetes with atherosclerotic disease and/or chronic kidney disease.
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Semaglutide reduced kidney disease progression and cardiovascular death risk in type 2 diabetes with chronic kidney disease.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Cagrilintide-semaglutide combination reduced body weight by 20.4% vs 3.0% with placebo.
Interactions
How it pairs with other peptides.
TIRZEPATIDE Caution · Well-documented
Caution: overlapping GLP-1 agonism with increased GI side effect risk. Generally not combined in clinical practice.
BPC-157 Neutral · Theoretical
No known negative interaction. BPC-157 may support GI health during GLP-1 therapy. Different mechanisms of action.
FAQ
Frequently asked questions.
Semaglutide is the GLP-1 agonist that revolutionized weight loss treatment. Following FDA resolution of shortages in 2025 and subsequent compounding restrictions, research-grade semaglutide has seen significant demand increases.